Cholesterol Drug
Amgen’s Repatha Reduces First-Time Cardiovascular Events by 25% in Major Clinical Trial
Amgen; Repatha; evolocumab; cholesterol drug; PCSK9 inhibitor; cardiovascular events; clinical trial; VESALIUS-CV; primary prevention; heart attack; LDL cholesterol